OA10698A - Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof. - Google Patents

Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof. Download PDF

Info

Publication number
OA10698A
OA10698A OA9800083A OA9800083A OA10698A OA 10698 A OA10698 A OA 10698A OA 9800083 A OA9800083 A OA 9800083A OA 9800083 A OA9800083 A OA 9800083A OA 10698 A OA10698 A OA 10698A
Authority
OA
OAPI
Prior art keywords
accordance
gssg
glutathione
oxidized glutathione
pharmaceutically acceptable
Prior art date
Application number
OA9800083A
Other languages
English (en)
Inventor
Mark Borisovich Balazovsky
Leonid Andreevich Kozhemyakin
Original Assignee
Mark Borisovich Balazovsky
Leonid Andreevich Kozhemyakin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mark Borisovich Balazovsky, Leonid Andreevich Kozhemyakin filed Critical Mark Borisovich Balazovsky
Publication of OA10698A publication Critical patent/OA10698A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
OA9800083A 1995-12-14 1998-06-12 Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof. OA10698A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU95120403/14A RU2089179C1 (ru) 1995-12-14 1995-12-14 Стимулятор эндогенной продукции цитокинов и гепопоэтических факторов и способ его использования
PCT/RU1996/000226 WO1997021443A1 (en) 1995-12-14 1996-08-08 Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof

Publications (1)

Publication Number Publication Date
OA10698A true OA10698A (en) 2002-11-26

Family

ID=20174317

Family Applications (1)

Application Number Title Priority Date Filing Date
OA9800083A OA10698A (en) 1995-12-14 1998-06-12 Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof.

Country Status (8)

Country Link
US (1) US6165979A (ru)
CN (1) CN1161149C (ru)
AU (1) AU6839196A (ru)
DK (1) DK0869809T3 (ru)
OA (1) OA10698A (ru)
PT (1) PT869809E (ru)
RU (1) RU2089179C1 (ru)
WO (1) WO1997021443A1 (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251857B1 (en) 1995-12-14 2001-06-26 Novelos Therapeutics, Inc. Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof
AU1890399A (en) 1998-01-19 1999-08-02 Takara Shuzo Co., Ltd. Substances capable of inducing apoptosis
JP2002509715A (ja) * 1998-03-30 2002-04-02 イ・デ・エム・イミュノ−デジネ・モレキュル 刺激された単球に由来する細胞、その調製及び用途
US6251868B1 (en) 1998-04-30 2001-06-26 Teijin Limited Method for treating a human immunodeficiency virus infection
US20070142267A1 (en) 1998-11-23 2007-06-21 Novelos Therapeutics, Inc. Methods for production of the oxidized glutathione composite with CIS-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
US6312734B1 (en) * 1998-11-23 2001-11-06 Novelos Therapeutics, Inc. Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
RU2144374C1 (ru) * 1998-11-23 2000-01-20 Закрытое акционерное общество "ВАМ" Способ получения композита окисленного глутатиона с cis-диаминодихлорплатиной и фармацевтических композиций на его основе, регулирующих метаболизм, пролиферацию, дифференцировку и механизмы апоптоза нормальных и трансформированных клеток
CA2453140C (en) * 2000-10-20 2016-01-05 Hamburger Stiftung Zur Forderung Von Wissenschaft Und Kultur Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins and from the inhibition thereof
DE10051983A1 (de) * 2000-10-20 2002-06-13 Beate Kehrel Inhibierung der pathogenen Wirkung oxidierter Proteine
US20030073618A1 (en) * 2001-02-08 2003-04-17 Kozhemyakin Leonid A. Compounds comprising disulfide-containing peptides and nitrogenous bases, and medical uses thereof
US7790762B2 (en) * 2002-10-31 2010-09-07 National Jewish Health Compounds and methods for thiol-containing compound efflux and cancer treatment
US20080221029A1 (en) * 2002-10-31 2008-09-11 Regents Of The University Of Colorado Methods for treatment of thiol-containing compound deficient conditions
US20040087527A1 (en) * 2002-10-31 2004-05-06 Day Brian J. Methods for treatment of thiol-containing compound deficient conditions
EA010926B1 (ru) * 2006-01-20 2008-12-30 Леонид Андреевич Кожемякин Средство для лечения туберкулеза глаз, способ его получения и применения
US20110064828A1 (en) * 2009-09-11 2011-03-17 Novelos Therapeutics, Incorporated Treatment of metastatic tumors and other conditions
RU2451010C1 (ru) * 2011-01-11 2012-05-20 Закрытое Акционерное Общество "Ива Фарм" Палладиево-медные катализаторы гомогенного селективного окисления тиольных групп, комбинация и композиция на их основе и способ терапевтического воздействия
JP6055408B2 (ja) * 2011-06-30 2016-12-27 株式会社カネカ 固体状酸化型グルタチオン塩及びその製造方法
RU2659161C1 (ru) 2017-11-17 2018-06-28 Общество С Ограниченной Ответственностью "Ива Фарм" Фармацевтическая композиция, включающая дисульфид глутатиона и глутатион дисульфид s-оксид
CN114425051A (zh) * 2022-03-07 2022-05-03 茂名市人民医院 硫辛酸在制备治疗脓毒症和/或脓毒性休克的药物中的应用
CN114617899B (zh) * 2022-04-14 2023-10-20 苏州大学附属儿童医院 S-腺苷甲硫氨酸在制备治疗脓毒血症相关性脑病药物中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1176983B (it) * 1984-10-16 1987-08-26 Zambon Spa Dipeptidi ad attivita' farmacologica
DE3784905T2 (de) * 1986-07-07 1993-08-05 Teijin Ltd Gamma-l-glutamyl-l-cysteinethylester und arzneimittel, die dieses als aktives mittel enthalten.
DE3768419D1 (de) * 1986-10-07 1991-04-11 Boehringer Biochemia Srl Pharmazeutische zusammensetzungen mit antineoplastischer wirkung.
US4968671A (en) * 1987-11-26 1990-11-06 Yamanouchi Pharmaceutical Co., Ltd. Therapeutic agents for ischemic heart diseases
JPH049336A (ja) * 1990-04-26 1992-01-14 Yasuo Komoda 催眠剤
US5248697A (en) * 1990-09-20 1993-09-28 Brigham And Women's Hospital Enhancement of glutathione levels with glutamine
ES2106096T3 (es) * 1991-02-04 1997-11-01 Nestle Sa Procedimiento para asegurar glutation intracelular adecuado en el tejido.
US5977073A (en) * 1991-06-06 1999-11-02 Life Sciences' Technologies, Inc. Nutrient composition for treatment of immune disorders
US5618823A (en) * 1992-06-24 1997-04-08 Boehringer Mannheim Italia S.P.A. Glutathione as chemoprotective agent
GB9303854D0 (en) * 1993-02-25 1993-04-14 Holt John A G Method for enhancing t-cell count
JPH11507056A (ja) * 1995-06-07 1999-06-22 テラピン テクノロジーズ、インク． グルタチオンアナログの代謝的効果
US5916878A (en) * 1995-11-28 1999-06-29 Edward T. Wei γ-glutamyl and β-aspartyl containing immunomodulator compounds and methods therewith

Also Published As

Publication number Publication date
AU6839196A (en) 1997-07-03
RU2089179C1 (ru) 1997-09-10
CN1207683A (zh) 1999-02-10
DK0869809T3 (da) 2002-07-29
CN1161149C (zh) 2004-08-11
PT869809E (pt) 2002-09-30
US6165979A (en) 2000-12-26
WO1997021443A1 (en) 1997-06-19

Similar Documents

Publication Publication Date Title
OA10698A (en) Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof.
EP0869809B1 (en) Oxidized glutathione as cytokine and hemopoietic factor endogenous production enhancer
ES2425083T3 (es) Agente antitumoral que comprende FK228 como inhibidor de histona desacetilasa y doxorrubicina como inhibidor de topoisomerasa II
ES2946179T3 (es) Efectos antineoplásicos de inhibidores de JAK2 en combinación con derivados de talidomida y glucocorticoides
Niwa et al. Effect of liposomal-encapsulated superoxide dismutase on active oxygen-related human disorders. A preliminary study
WO1997021444A9 (en) Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof
US5318957A (en) Method of stimulating angiogenesis
JP2012149095A (ja) ガンを治療するための組成物とｅｔ７４３の使用
Burke et al. Imidazole carboxamide therapy in advanced malignant melanoma
US6251857B1 (en) Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof
JP2011506467A (ja) 抗悪性腫瘍性熱ショックアポトーシス活性化因子（ｈｓａａ）と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法
ES2254408T3 (es) Procedimiento de tratamiento de tumores usando terapia fotodinamica.
US5219565A (en) Treatment of primary cancers of the pleura
US20160022762A1 (en) Agent for Eliminating Multidrug Resistance
WO1993008821A1 (en) Side effect inhibitor for cancer therapy
JPS6366128A (ja) 動物およびヒト癌の治療に用いられるｃ反応性タンパク質
Erlichman et al. Phase I trial of N-(phosphonacetyl)-L-aspartate
Ichikawa Chemotherapy of penis carcinoma
JP3030386B2 (ja) 抗ガン剤
RU2153351C2 (ru) Средство для регулирования эндогенной продукции цитокинов и гемопоэтических факторов (варианты) и способ его использования
Comella et al. Oxaliplatin and raltitrexed combined with leucovorin-modulated 5-fluorouracil iv bolus every two weeks: A dose finding study in advanced previously treated colorectal carcinoma
IJzermans et al. Injection of recombinant tumor necrosis factor directly into liver metastases: an experimental and clinical approach
ATE210978T1 (de) Pharmazeutische zusammensetzung enthaltend uscharin
Gresser et al. Effectiveness of Mouse Interferon α/β Compared to Single-Agent Chemotherapy in Increasing Survival Time of Mice After Intravenous Inoculation of Friend Erythroleukemial Cells
JP3064815B2 (ja) ミエローマ系腫瘍抗癌剤